This guideline synthesizes clinical trial data supporting the role of glucagon-like peptide-1
receptor agonists and sodium-glucose co-transporter 2 inhibitors (SGLT2i) for treatment of …

Objective The role of glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of
type 2 diabetes is debated; many recent trials, which were not included in previous meta …

The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …

The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are released from enteroendocrine cells in response to the …

Patients with type 2 diabetes exhibit higher cardiovascular risk than normal individuals.
Optimal blood glucose levels are rarely achieved in diabetic patients. Glucagon‑like peptide …

Current management options for treating type 2 diabetes are diverse. Many different classes
of antidiabetes therapies are used in clinic, and several new candidates are in late-phase …

Background Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally
similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular …

Background Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal
outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the …

What is known and objective In recent years, glucagon‐like peptide‐1 receptor agonists
(GLP‐1 RAs) including once‐weekly (QW) formulations have been incorporated into type 2 …